Business Monitor International


Kuwait Pharmaceuticals & Healthcare Report

Published 11 March 2014

  • 120 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Kuwait Pharmaceuticals & Healthcare Report

BMI View: With the Kuwaiti government's continued commitment to austerity, spending on healthcare provision for expatriate workers ( which form s nearly two-thirds of its population ) is going to be thoroughly scrutinised. New hospitals are being planned for expatriate workers and infrastructure development will continue to be a key area of growth, in addition to opportunities for private healthcare insurance providers to serve the expatriate market. The g overnment's focus on non-communicable disease control will continue to provide lucrative opportunities for pharmaceutical companies.

Headline Expenditure Projections

  • Pharmaceuticals: KWD290mn (US$1.03bn) in 2013 to KWD306mn (US$1.10bn) in 2014; +5.6% in local currency terms and +6.8% in US dollar terms. Forecast raised to +6.8% in US$ terms for 2014.

  • Healthcare: KWD1.50bn (US$5. 35bn) in 2013 to KWD1.67bn (US$6.00bn) in 2014; +10.9% in local currency terms and +12.1% in US dollar terms. Forecast raised to 12.1% in US$ terms for 2014.

Risk/Reward Rating

Kuwait scored 58.5 in BMI's Pharmaceutical Risk/Reward Rating (RRR) for Q214; a slight improvement in its score from Q413. Kuwait has risen to second place, behind Saudi Arabia, out of a total of 30 markets.

Key Trends And Developments

In February 2014, the system of allotting the morning/day shift to Kuwait citizens and GCC nationals, while allotting the evening shift to expatriates, is set to continue receiving approval from Dr Abdul Aziz Al- Farhood, the director of the Jahra District, the Arab Times reports. According to the paper, the system now applies to other health districts and evening shifts are also expected to be allotted to Bedouins. Earlier in January 2014, the Kuwaiti government terminated the services of 2,233 expatriate workers with conditions such as HIV AIDS and hepatitis C, and sent them back to their countries, the Arab Times reports.

In February 2014, Kuwait's Health Minister Ali Al-Obaidi during his visit to Turkey said that...

Table of Contents

BMI Industry View
7
SWOT
9
Political SWOT
11
Economic SWOT
12
Business Environment SWOT
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales Indicators, 2010-2018
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Indicators, 2010-2018
20
Table: Healthcare Governmental Indicators, 2010-2018
20
Table: Healthcare Private Indicators 2010-2018
21
Prescription Drug Market Forecast
22
Table: Prescription Drug Sales Indicators 2009-2017
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, 2010-2018
25
Generic Drug Market Forecast
26
Table: Generic Drug Sales Indicators, 2010-2018
27
OTC Medicine Market Forecast
28
Table: OTC Medicine Sales Indicators, 2010-2018
29
Pharmaceutical Trade Forecast
30
Table: Kuwait Pharmaceutical Trade Data
31
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Table: Kuwait - Economic Activity
43
Industry Risk Reward Ratings
44
Middle East And Africa Risk/Reward Ratings
44
Kuwait Risk/Reward Ratings
52
Rewards
52
Risks
52
Market Overview
54
Industry Trends And Developments
56
Epidemiology
56
Healthcare Sector
60
Table: Hospital Name, Speciality And Number Of Beds
61
Healthcare Sector Developments
62
Healthcare Insurance
70
Research And Development
71
Clinical Trials
72
Regulatory Development
73
Regulatory Regime
73
Intellectual Property Issues
74
Pricing Regime
75
Reimbursement Regime
77
Competitive Landscape
82
Domestic Industry
82
Foreign Industry
84
Pharmaceutical Distribution
85
Company Profile
86
Kuwait-Saudi Pharmaceutical Industries (KSP)
86
Advanced Technology Company
88
Bader Sultan & Bros
91
Safwan Trading and Contracting Company
94
Novartis
97
Sanofi
99
Pfizer
101
GlaxoSmithKline
103
Merck & Co
105
Johnson & Johnson
107
Demographic Forecast
109
Demographic Outlook
109
Table: Kuwait's Population By Age Group, 1990-2020 ('000)
110
Table: Kuwait's Population By Age Group, 1990-2020 (% of total)
111
Table: Kuwait's Key Population Ratios, 1990-2020
112
Table: Kuwait's Rural And Urban Population, 1990-2020
112
Glossary
113
Methodology
115
Pharmaceutical Expenditure Forecast Model
115
Healthcare Expenditure Forecast Model
115
Notes On Methodology
116
Risk/Reward Ratings Methodology
117
Ratings Overview
118
Table: Pharmaceutical Risk/Reward Ratings Indicators
118
Indicator Weightings
119

The Kuwait Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kuwait Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kuwaiti pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kuwait to test other views - a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Kuwaiti pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kuwait.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc